EZH2 and neoplasm: Suppressing EZH2 activity by EZH2 inhibitor GSK126 resulted in more myeloid-derived suppressor cells (MDSC) and less CD4+ and IFNγ+CD8+ T cells accumulated in tumors, which are key components of anti-tumor immunity, suggesting that EZH2 inhibitors may exhibit antitumor efficacy by modulating tumor immune microenvironment [58].